Target Name: ATP6V0CP1
NCBI ID: G100132978
Review Report on ATP6V0CP1 Target / Biomarker Content of Review Report on ATP6V0CP1 Target / Biomarker
ATP6V0CP1
Other Name(s): ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c (ATP6VOC) pseudogene | ATPase H+ transporting V0 subunit c pseudogene 1 | ATP synthase subunit C domain containing 1 pseudogene | ATPase H+ transporting subunit c pseudogene 1 | ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c pseudogene 1 | ATCD1

Unlocking the Potential of ATP6V0CP1: A novel Drug Target and Biomarker

ATP6V0CP1, also known as Parp6, is a protein that plays a crucial role in DNA repair and protection. It is a key component of the homologous recombinase (HRR) complex, which is responsible for repairing DNA double-strand breaks in damaged cells. The HRR complex is a highly conserved protein complex that has been identified as a potential drug target in various diseases, including cancer.

The discovery of ATP6V0CP1 as a drug target and biomarker has significant implications for the development of new therapeutic approaches. In this article, we will explore the structure and function of ATP6V0CP1, discuss its role in the HRR complex, and highlight its potential as a drug target and biomarker.

Structure and Function

ATP6V0CP1 is a 21 kDa protein that contains 119 amino acid residues. It belongs to the nucleotide diphosphatase (NDP) family 1, which is characterized by the presence of a nucleotide-binding domain and a catalytic domain. The NDP family is involved in the regulation of DNA replication, repair, and post-translational modifications, making ATP6V0CP1 a potential drug target.

ATP6V0CP1 functions as a key component of the HRR complex, which is responsible for repairing DNA double-strand breaks in damaged cells. The HRR complex is a highly conserved protein complex that has been identified as a potential drug target in various diseases, including cancer. The HRR complex includes several subunits, including Parp1, Parp2, Parp3, Parp4, Parp5, Parp6, and Parp7, which are involved in the distinct stages of DNA double-strand break repair.

ATP6V0CP1 plays a crucial role in the HRR complex by participating in the repair of double-strand breaks in the repair intermediateates, which are formed during the initial stage of the repair process. Specifically, Parp6 is involved in the formation of the double-strand break repair intermediateates, which are then processed by other subunits of the HRR complex to complete the repair process.

In addition to its role in the HRR complex, ATP6V0CP1 has also been shown to play a critical role in the regulation of DNA replication and repair in various organisms, including humans. For example, studies have shown that Parp6-deficient cells have reduced DNA repair efficiency and are more susceptible to DNA damage, which may contribute to the development of cancer.

Potential Therapeutic Applications

The discovery of ATP6V0CP1 as a drug target has significant implications for the development of new therapeutic approaches. One potential approach is to target Parp6 to treat DNA-related diseases, such as cancer.

ATP6V0CP1 has been shown to play a critical role in the regulation of DNA replication and repair in various organisms, including humans. Therefore, inhibiting Parp6 activity may be an effective way to treat DNA-related diseases, such as cancer.

Another potential approach is to target Parp6 to treat genetic disorders that are caused by defects in DNA repair. For example, Parp6-deficient mice have been shown to have reduced DNA repair efficiency and are more susceptible to DNA damage, which may contribute to the development of certain genetic disorders. Therefore, targeting Parp6 to

Protein Name: ATPase H+ Transporting V0 Subunit C Pseudogene 1

The "ATP6V0CP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP6V0CP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ATP6V0CP3 | ATP6V0D1 | ATP6V0D1-DT | ATP6V0D2 | ATP6V0E1 | ATP6V0E1P1 | ATP6V0E2 | ATP6V0E2-AS1 | ATP6V1A | ATP6V1B1 | ATP6V1B2 | ATP6V1C1 | ATP6V1C2 | ATP6V1D | ATP6V1E1 | ATP6V1E2 | ATP6V1F | ATP6V1FNB | ATP6V1G1 | ATP6V1G1P1 | ATP6V1G2 | ATP6V1G2-DDX39B | ATP6V1G3 | ATP6V1H | ATP7A | ATP7B | ATP8 | ATP8A1 | ATP8A2 | ATP8B1 | ATP8B1-AS1 | ATP8B2 | ATP8B3 | ATP8B4 | ATP8B5P | ATP9A | ATP9B | ATPAF1 | ATPAF2 | ATPase | ATPSCKMT | ATR | ATRAID | Atrial natriuretic peptide (ANP) receptor | ATRIP | ATRN | ATRNL1 | ATRX | ATXN1 | ATXN10 | ATXN1L | ATXN2 | ATXN2L | ATXN3 | ATXN3L | ATXN7 | ATXN7L1 | ATXN7L2 | ATXN7L3 | ATXN7L3B | ATXN8OS | Augmin | AUH | AUNIP | AUP1 | AURKA | AURKAIP1 | AURKAP1 | AURKB | AURKC | Aurora Kinase | AUTS2 | AVEN | AVIL | AVL9 | AVP | AVPI1 | AVPR1A | AVPR1B | AVPR2 | AWAT1 | AWAT2 | AXDND1 | AXIN1 | AXIN2 | AXL | Axonemal dynein complex | AZGP1 | AZGP1P1 | AZGP1P2 | AZI2 | AZIN1 | AZIN2 | AZU1 | B-cell Antigen Receptor Complex | B2M | B3GALNT1 | B3GALNT2 | B3GALT1 | B3GALT1-AS1